Contents
Special Issue Topic

Antibody-Drug Conjugates

Guest Editors

Dr. Francesco Bertoni E-Mail

Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland

Research Keywords: lymphoma; novel drugs; genomics; BET; PI3K

Dr. Anastasios Stathis E-Mail

Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland; Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland

About the Special lssue

Antibody drug conjugates (ADCs) have become a potent modality to treat solid tumors and hematologic malignancies. The use of antibodies against antigens that are the most specific as possible for cancer cells and that bear particular biologic features allow the delivery of powerful payloads, which otherwise would be too toxic. 

With some of the first-generation compounds already approved by regulatory agencies, there is still wide room for further improvements of this therapeutic approach. ADC-incorporating regimens, novel linkers, novel targets, novel payloads are all exciting fields of preclinical and clinical research.

This special issue of Exploration of Targeted Anti-tumor Therapy covers all the aspects of the use of ADCs, inviting investigators to submit their novel lab and clinical findings.

Keywords: Antibody drug conjugate; ADC; payload; linker; antibody

Published Articles

Open Access Review
Antibody-drug conjugates combinations in cancer treatment
Giulia Pretelli ... Anastasios Stathis
Published: June 27, 2024 Explor Target Antitumor Ther. 2024;5:714–741
3121 61 2
Open Access Review
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Marilia Barreca ... Francesco Bertoni
Published: December 26, 2022 Explor Target Antitumor Ther. 2022;3:763–794
4325 77 17
Open Access Review
Antibody-drug conjugates: beyond current approvals and potential future strategies
Siddharth Menon ... Hui K. Gan
Published: April 28, 2022 Explor Target Antitumor Ther. 2022;3:252–277
8701 248 17
Open Access Review
Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
Marta Nerone ... Ilaria Colombo
Published: April 19, 2022 Explor Target Antitumor Ther. 2022;3:149–171
6375 140 5
Open Access Review
New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
Kira-Lee Koster ... Markus Joerger
Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36
5551 105 19
Open Access Review
Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
Monique Hartley-Brown, Paul Richardson
Published: January 14, 2022 Explor Target Antitumor Ther. 2022;3:1–10
4589 131 6
Open Access Original Article
Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
Tomohiro Fujii ... Yutaka Matsuda
Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:576–585
4876 199 12